NBT 011

Drug Profile

NBT 011

Alternative Names: ABI-011; IDN 5404; IND-5404; nab-5404; nab-IND-5404; NTB-011

Latest Information Update: 26 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Abraxis BioScience; Indena
  • Developer Celgene Corporation
  • Class Antineoplastics; Colchicum alkaloids; Drug conjugates
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Oct 2015 NantBioScience plans a phase I trial for Solid tumours (Late-stage disease) and Lymphoma (Late-stage disease) in USA (IV) (NCT02582827)
  • 13 Jan 2014 NTB 011 licensed to NantBioScience
  • 14 Mar 2011 Phase-I clinical trials in Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top